Pharmause AB
ABActiveOrg 5592454762MalmöDiagnostic imaging services and medical laboratory activities· NACE 8691Est. 2020 · 6 years old0 employees
Loading company…
Overview
Pharmause AB is a Swedish AB based in Malmö, operating in the Diagnostic imaging services and medical laboratory activities sector. Incorporated in 2020, the company has 0 employees and reported revenue of SEK 0 in its latest annual filing.
Revenue 2025
0K SEK
EBITDA margin
—
Net profit 2025
-17K SEK
+61% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
100.0 %
Very strongAmong the 10% highest rated companies in the industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
0.0×
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
-2.9 %
WeakAmong the 30% lowest rated companies in the industry
20212025
EBITDA — year on year
SEK millionsKey figures
Annual report 2025| Revenue | 0K SEK | — |
| EBITDA | -7.4K SEK | +66% |
| Net profit | -17K SEK | +61% |
| Total assets | 586K SEK | -24% |
| Equity | 586K SEK | -3% |
| Employees | 0 | — |
Company information
Legal name
Pharmause AB
Org number
5592454762
Legal form
Aktiebolag
NACE code
Founded
2 March 2020 · 6 years
Share capital
SEK 25,000
Employees
0 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva hjälp med konsultering vid internationell handel och därmed förenlig verksamhet.
(no translation available)
Contact
Address
Email
info@pharmause.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Pharmause AB reported revenue of SEK 0. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of SEK 17.0k.
At the end of 2025, equity financed 100% of the balance sheet.
Financials
Revenue
SEK millionsEBITDA
SEK millionsIncome statement
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 4,269 | 57,604 | 118,408 |
| Staff expenses | — | -0 | -2,294 | -10,134 | — |
| EBITDA | -7 | -22 | -1,091 | 9,370 | 21,276 |
| Depreciation & amort. | — | — | -251 | -410 | -318 |
| EBIT | -7 | -22 | -1,342 | 8,960 | 20,958 |
| Net financials | -10 | -21 | 127 | — | -113 |
| Profit before tax | -17 | -43 | 785 | — | 21,095 |
| Tax | — | — | 164 | 1,424 | -4,500 |
| Net profit | -17 | -43 | 621 | 5,420 | 16,595 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 586 | 774 | 2,522 | 0 | 34,436 |
| Equity | 586 | 603 | 646 | 0 | 17,214 |
| Long-term debt | — | — | 0 | 0 | 0 |
| Short-term debt | 0 | 171 | 1,876 | 0 | 17,223 |
| Total debt | — | 171 | 1,876 | 0 | 17,223 |
Financial ratios
5-year trendEBITDA margin
<−999 %
20212025
Equity ratio
100.0 %
Very strongAmong the 10% highest rated companies in the industry
20212025
Return on equity
-2.9 %
WeakAmong the 30% lowest rated companies in the industry
20212025
Net profit margin
<−999 %
20212025
Asset turnover
0.00×
Very weakAmong the 10% lowest rated companies in the industry
20212025
Debt / equity
0.00×
20212025
Sector performance
13 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Basic earning power (BEP)Weak
Among the 30% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on net assets (RONA)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Capacity ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current assets to equityStrong
Among the 30% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Cash conversion ratioVery weak
Among the 20% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Fixed assets to long-term capitalNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Debt & solvency
Solidity ratioVery strong
Among the 10% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Liabilities to equityVery strong
Among the 10% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Interest coverageWeak
Among the 30% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery weak
Among the 10% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery weak
Among the 20% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Debt ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Income to debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBITDA relative to debt — how much operating earnings are available to service the debt.
Efficiency & development
Asset turnoverVery weak
Among the 10% lowest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Equity to contributed capitalStrong
Among the 30% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityWeak
Among the 40% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
One-year change in debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|
Former (3)
AF | Audit | 2022 – 2024 |
HD Audit | Audit | 2021 – 2022 |
JE Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SD Board of Directors | Board of Directors | 2020 |
PD Deputy Board Member | Deputy Board Member | 2022 |
Former (5)
LA Deputy Board Member | Deputy Board Member | 2020 – 2020 |
KK Deputy Board Member | Deputy Board Member | 2020 – 2021 |
KS Board of Directors | Board of Directors | 2020 – 2020 |
PM Deputy Board Member | Deputy Board Member | 2020 – 2020 |
NH Deputy Board Member | Deputy Board Member | 2020 – 2020 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
KKDH AB
Pharmause AB Board network connections
Board members of Pharmause AB also hold positions in 58359 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 21,851 companiesMany roles |
| Karl-Johan Staffan Tångby | Board of Directors | 21,850 companiesMany roles |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 14,204 companiesMany roles |
| Anders Filip Lundberg | Audit | 443 companiesMany roles |
| Prabha Duggal | Deputy Board Member | 5 companies |
| Jesper Erik Ottosson | Chief Executive Officer | 2 companies |
| Sumit Duggal | Board of Directors | 2 companies |
| Khushi Khushdeep Singh | Deputy Board Member | 2 companies |
Frequently asked questions
What is the Org number of Pharmause AB?
Pharmause AB is registered with Bolagsverket / SCB under Org 5592454762.
Where is Pharmause AB headquartered?
Pharmause AB's registered address is Malmö.